Ronald L. Trowbridge (The Hill, 4/16/20)

Hydroxychloroquine has not been approved by the FDA for COVID-19—leading many to criticize Trump, an advocate for its use. But the FDA has approved hydroxychloroquine as safe for patients with malaria, lupus, and arthritis. Using it for COVID-19 would be off-label, yet about 20 percent of all drug usage in the country is off-label. READ MORE »
 

Richard A. Epstein (4/10/20)

The coronavirus crisis raises two urgent questions for the United States. First, what is the likely number of deaths from the coronavirus, in either the absence or presence of social intervention? Second, in light of the limited resources that are available, what is the set of tools, both coercive and noncoercive, that should be used to implement the most effective interventions? READ MORE »
 

Richard K. Vedder (Forbes, 4/13/20)

No one knows the precise financial damage that the COVID-19 pandemic will inflict on American colleges and universities—or how much aid stressed federal, state, and local governments will be able, or willing, to deliver to them. One of the likely casualties of this uncertainty? Tenure. READ MORE »
 

Gary M. Galles (4/9/20)

Certain medical experts with media megaphones have been putting forward potentially catastrophic scenarios, along with drastic plans to deal with them. However, having medical expertise does not make one an expert on government policy. READ MORE »
 

John C. Goodman (Forbes, 4/13/20)

A revolution in the way medical care is delivered in the United States is upon us. Doctors and patients are now communicating by means of phone, email, Skype, Zoom and other devices. If you are like a great many people, you are probably wondering why it took so long. READ MORE »